Gã khổng lồ dược phẩm AstraZeneca của Anh đang đối diện nghi vấn trốn thuế nhập khẩu tại Trung Quốc cho hai loại thuốc điều trị ung thư.

Hãng AstraZeneca ngày 1/6 đã cập nhật thông tin về hiệu quả của thuốc điều trị ung thư vú Camizestrant với kết quả được đánh giá là mang tính đột phá ...

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.

AstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company tries to grab a slice of the booming weight-loss market and aims to almost double ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and tolerable in an early-stage trial, with side effects ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

p style="text-align: justify;">(GLO)- Thuốc Datroway của AstraZeneca vừa được Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) phê chuẩn điều trị ung thư phổi không tế bào nhỏ. Đây cũng là loại thuốc t ...

AstraZeneca Plc agreed to buy US biotech CinCor Pharma Inc. for as much as $1.8 billion to gain a promising new treatment for hypertension and kidney disease.

Britain's AstraZeneca has agreed to pay $425 million to settle about 11,000 lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.

Topline AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common ...

Topline AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular ...